HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ulocuplumab

Also Known As:

BMS-936564; MDX-1338

Networked: 6 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Ghobrial, Irene M: 2 articles (10/2021 - 01/2020)
2.	Sabbatini, Peter: 2 articles (01/2020 - 01/2016)
3.	Cardarelli, Pina M: 2 articles (01/2016 - 01/2013)
4.	Cohen, Lewis J: 2 articles (01/2016 - 01/2013)
5.	Kuhne, Michelle R: 2 articles (01/2016 - 01/2013)
6.	Mehrpouri, Mahdieh: 1 article (04/2022)
7.	Branagan, Andrew R: 1 article (10/2021)
8.	Cao, Yang: 1 article (10/2021)
9.	Castillo, Jorge J: 1 article (10/2021)
10.	Demos, Maria G: 1 article (10/2021)

Related Diseases

1.	Hematologic Neoplasms (Hematological Malignancy) 01/19/2016 - "Overall, these findings are evidence that Ulocuplumab (BMS-936564) has biological activity in CLL, highlight the relevance of the CXCR4-CXCL12 pathway as a therapeutic target in CLL, and provide biological rationale for ongoing clinical trials in CLL and other hematological malignancies." 04/05/2022 - "Plerixafor, BKT140, LY2510924, PF-06747143, ulocuplumab, and NOX-A12 are among the most well-known CXCR4 and CXCL12 modulators that their therapeutic efficacies have been evaluated in different pre-clinical and clinical studies of hematologic malignancies. "
2.	Multiple Myeloma 01/15/2013 - "When given as monotherapy, MDX-1338 exhibits antitumor activity in established tumors including AML, NHL, and multiple myeloma xenograft models. " 01/01/2020 - "This phase Ib/II study aimed to determine the safety and tolerability of ulocuplumab alone and in combination with lenalidomide and dexamethasone (Arm A), or bortezomib and dexamethasone (Arm B), in patients with relapsed/refractory multiple myeloma. " 01/01/2020 - "A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma."
3.	Waldenstrom Macroglobulinemia (Macroglobulinemia) 10/28/2021 - "Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia."
4.	Neoplasms (Cancer) 01/15/2013 - "In addition, we show that MDX-1338 induced apoptosis on a panel of cell lines and propose that antibody-induced apoptosis is one of the mechanisms of tumor growth inhibition. " 01/15/2013 - "When given as monotherapy, MDX-1338 exhibits antitumor activity in established tumors including AML, NHL, and multiple myeloma xenograft models. " 04/01/2016 - "Immune checkpoint inhibitors such as ipilimumab, nivolumab, pembrolizumab, durvalumab, tremelimumab and ulocuplumab are at the forefront of immunotherapy and have achieved approvals for certain cancer types, including melanoma (ipilimumab, nivolumab and pembrolizumab), non-SCLC (nivolumab and pembrolizumab) and renal cell carcinoma (nivolumab). "
5.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/19/2016 - "Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway."

Related Drugs and Biologics

1.	Dexamethasone (Maxidex)
2.	Lenalidomide (CC 5013)
3.	Bortezomib (Velcade)
4.	NOX-A12
5.	BKT140
6.	ibrutinib
7.	plerixafor
8.	LY2510924
9.	Reactive Oxygen Species (Oxygen Radicals)
10.	Immune Checkpoint Inhibitors

Related Therapies and Procedures

1.	Immunotherapy